Brief: BiomX Announces Positive Results From Part 1 Of The Phase 1B/2A Study Evaluating BX004 For Treatment Of Chronic Pulmonary Infections In Patients With Cystic Fibrosis
Feb 22 (Reuters) - Biomx Inc PHGE.A :
* BIOMX ANNOUNCES POSITIVE RESULTS FROM PART 1 OF THE PHASE
1B/2A
STUDY EVALUATING BX004 FOR TREATMENT OF CHRONIC PULMONARY
INFECTIONS IN PATIENTS WITH CYSTIC FIBROSIS
* BIOMX INC: BX004 THERAPY SAFE AND WELL-TOLERATED ACROSS
ALL
PATIENTS AND DOSE LEVELS
* BIOMX INC: PRELIMINARY SIGNALS OF EFFICACY ALSO OBSERVED,
WITH
NOTABLE REDUCTIONS IN BACTERIAL BURDEN
* BIOMX INC: DOSING IN PATIENTS IN PART 2 INITIATED, RESULTS
EXPECTED IN Q3 23
Source text for Eikon: ID:nGNX6BD2pN
Further company coverage: PHGE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tessera Defense and Homeland Security
See all newsBrief: Tessera Defense & Homeland Security - Enters $5 Million Revolving Credit Agreement With Mandragola On Oct 5, 2026 - SEC Filing
Brief: Biomx - Announces One-For-Ten Reverse Stock Split Of Common Stock - SEC Filing
Brief: Biomx And Water.Io Agree To Updated Zorronet Acquisition Terms
Brief: BiomX - May Offer And Sell Up To $9.10 Million Of Common Stock Through Wainwright - SEC Filing
Brief: Biomx Provides Update On Defense Technology Portfolio And Growth Strategy